On November 10, 2015 it was announced that Ocata had been acquired by Astellas Pharma for $379M. Previously known as Advanced Cell Technology Inc, In November the firm was renamed Ocata Therapeutics, Inc with change of its trading info to NASDAQ:OCAT. Ocata is a clinical stage biotechnology company, working in the regenerative ophthalmology therapeutics space. Various clinical trials are underway for treating Stargardt?s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. The firm's intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The intellectual property portfolio also comprises cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs.
